A Post-Market Clinical Evaluation of the Treatment of Tibia Fractures With the T2 Alpha Tibia Nailing System
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tibial Fractures
- Sponsor
- Stryker Trauma and Extremities
- Enrollment
- 103
- Locations
- 4
- Primary Endpoint
- SF-36 PCS (36-Item Short Form Health Survey Physical Component Summary)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This investigation is a prospective, multi-center clinical investigation. It is anticipated that a total of 80 subjects will be enrolled. Neither subjects nor investigators are blinded to treatment and the clinical investigation includes a historical control which will be compared to the T2 Alpha Tibia Nailing System.
Total duration of enrollment, 12 month follow-up and analysis is expected to take 31 months. The clinical investigation has been designed to follow the surgeon's standard of care for tibia fractured subjects, in addition to a 12 month follow-up visit.
The primary endpoint of this clinical investigation is to confirm efficacy/performance at 12 months, as measured by the SF-36 Physical Component Summary (PCS). Confirmation of efficacy/performance at 12 months will be based on an equal or higher (non-inferior) SF-36 Physical Component Summary (PCS) result of the T2 Alpha Tibia Nailing System compared to the benchmark literature.
Detailed Description
The objective of this clinical investigation is to demonstrate the safety and efficacy/performance of the T2 Alpha Tibia Nailing System. Efficacy/performance of the procedure will be measured by an equal or higher (non-inferior) SF-36 Physical Component Summary (PCS) score result of the T2 Alpha Tibia Nailing System compared to the T2 Tibia benchmark literature at 12 months. In addition, demonstration of bone consolidation in correct alignment will be measured by Investigator assessment by 12 months. Safety of the T2 Alpha Tibia Nailing System will be demonstrated through reporting of device related intra-operative and post-operative Adverse Events/incidents by 12 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject is a male or non-pregnant female age 18 years or older at the time of surgery;
- •Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan;
- •Subject is intended to be, treated with the Tibial Nail of the T2 Alpha Tibia Nailing System in accordance with the following legally cleared/ approved Indications for Use:
- •Indications for Use approved In United States and Canada include:
- •Open and closed tibial fractures
- •Pseudoarthrosis and correction osteotomy
- •Pathologic fractures, impending pathologic fractures and tumor resections
- •Fractures involving osteopenic and osteoporotic bone
- •Nonunions and malunions
Exclusion Criteria
- •Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results;
- •Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e. significant circulatory problems, cardiac disease).
Outcomes
Primary Outcomes
SF-36 PCS (36-Item Short Form Health Survey Physical Component Summary)
Time Frame: 12 months
The primary endpoint of this clinical investigation is to confirm efficacy/performance at 12 months, as measured by the SF-36 PCS (36-Item Short Form Health Survey Physical Component Summary). The SF-36 PCS is a self-report measure of health status. SF-36 Physical Component Summary scores range from 0 to 100; higher SF-36 score results are linked to better subject results. Confirmation of efficacy/performance at 12 months will be based on an equal or higher (non-inferior) SF-36 Physical Component Summary (PCS) result of the T2 Alpha Tibia Nailing System compared to the T2 Tibia benchmark literature.
Secondary Outcomes
- Safety Will be Measured by Capturing the Incidence Rate of Device-related Adverse Events(12 months)
- Efficacy/Performance Will be Measured by Demonstration of Bone Consolidation(12 months)